Abalos Therapeutics launches with €12M in Series A funding to get the development of its arenavirus-based cancer therapies off the ground.
Boehringer Ingelheim Venture Fund and Gründerfonds Ruhr co-led the investment round, with additional contributions from NRW.BANK and High-Tech Gründerfonds.
Abalos, which is based in Essen, Germany, will focus on developing anti-cancer drugs with specific arenaviruses that can infect cancer cells and generate a strong immune response from the body against the tumor.